Adela Turcanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adela Turcanu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Angela Paraschiv
“Nicolae Testemitanu” Moldova State University of Medicine and Pharmacy
1 shared publication - Anika Wranke
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
1 shared publication - Blaj Valentina
National Agency for Public Health
1 shared publication - Cihan Yurdaydin
Department of Gastroenterology & Hepatology Koç University Medical School Istanbul Turkey
1 shared publication - Cirley Maria de Oliveira Lobato
Universidade Federal do Acre, Brazil; Secretaria Estadual de Saúde do Acre, Brazil
1 shared publication - Daniela Buruiana
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 30-33
Rolul factorului von willebrand în boala hepatică cronică
Patients with advanced chronic liver disease present alterations in all phases of hemostasis. Clinical evidence suggests a link between liver disease and changes in von Willebrand factor (VWF) which is supported by emerging mechanistic data showing a negative role of VWF in liver disease progression. Elevated VWF levels accelerate intrahepatic thrombus formation and therefore may be a determinant of disease progression. This review focuses on the clinical and experimental evidence supporting a link between VWF function and the progression of chronic liver disease. A comprehensive bibliographic search was performed using the PubMed, Scopus, and Web of Science databases for articles published up to June 1, 2025. Search terms included combinations of: “von Willebrand factor”, “liver disease”, “cirrhosis”, “portal vein thrombosis”. VWF/ADAMTS13 imbalance correlates with severity of liver disease and poor prognosis in liver disease. Von Willebrand factor is a promising noninvasive biomarker of endothelial dysfunction and liver disease progression, as well as a novel therapeutic target.
- 1 October 2025
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 2(104),p. 30-33
Open AccessRolul factorului von willebrand în boala hepatică cronică
Patients with advanced chronic liver disease present alterations in all phases of hemostasis. Clinical evidence suggests a link between liver disease and changes in von Willebrand factor (VWF) which is supported by emerging mechanistic data showing a negative role of VWF in liver disease progression. Elevated VWF levels accelerate intrahepatic thrombus formation and therefore may be a determinant of disease progression. This review focuses on the clinical and experimental evidence supporting a link between VWF function and the progression of chronic liver disease. A comprehensive bibliographic search was performed using the PubMed, Scopus, and Web of Science databases for articles published up to June 1, 2025. Search terms included combinations of: “von Willebrand factor”, “liver disease”, “cirrhosis”, “portal vein thrombosis”. VWF/ADAMTS13 imbalance correlates with severity of liver disease and poor prognosis in liver disease. Von Willebrand factor is a promising noninvasive biomarker of endothelial dysfunction and liver disease progression, as well as a novel therapeutic target.
- Open Access
- 1 June 2025
- Published by Asociatia de Biosiguranta si Biosecuritate din Republica Moldova in One Health & Risk Management
- Vol. 6 (2) , 33-44
Seroprevalence of hepatitis e virus in five high-risk populations from the Republic of Moldova: a cross-sectional study
Introduction. The study assessed the seroprevalence of Hepatitis E virus (HEV) markers in different at-risk groups within the Republic of Moldova. The risk groups included blood donors, hemodialysed patients, medical workers, tuberculosis (TB) patients, and intravenous drug users (IDUs). Material and methods. A cross-sectional descriptive-epidemiological study was conducted from 2019 to 2023, with participants randomly selected from different risk groups. Blood samples were collected and tested using ELISA for Anti-HEV IgG and IgM markers. Seroprevalence was calculated with 95% confidence intervals, and statistical analyses were conducted using Epi Info 7.2 software. Results. Among 794 tested blood donors, 9.6% (95% CI: 7.7-11.8) were positive for Anti-HEV IgG, indicating past exposure, and 8.3% (95% CI: 6.3-10.8) for Anti-HEV IgM, suggesting recent infection. Hemodialyzed patients had a significantly higher seroprevalence: 45.8% (95% CI: 34.8–57.1) for Anti-HEV IgG and 21.6% (95% CI: 9.8–38.2) for Anti-HEV IgM. Medical workers exhibited moderate IgG prevalence at 11.8% (95% CI: 9.1-15.0) and substantially higher IgM prevalence at 38.1% (95% CI: 26.1-51.2). TB patients had lower IgG (11.9%, 95% CI: 7.8-17.2) and IgM (7.8%, 95% CI: 3.6-14.3) prevalences. IDUs had a notable IgG prevalence of 20.5% (95% CI: 12.6-30.4) but no detectable IgM. Conclusions. This study highlights the significant burden of hepatitis E virus infection among at-risk populations in the Republic of Moldova.
- 1 June 2025
- Published by Asociatia de Biosiguranta si Biosecuritate din Republica Moldova in One Health & Risk Management
- Vol. 6 (2) , 33-44
Open AccessSeroprevalence of hepatitis e virus in five high-risk populations from the Republic of Moldova: a cross-sectional study
Introduction. The study assessed the seroprevalence of Hepatitis E virus (HEV) markers in different at-risk groups within the Republic of Moldova. The risk groups included blood donors, hemodialysed patients, medical workers, tuberculosis (TB) patients, and intravenous drug users (IDUs). Material and methods. A cross-sectional descriptive-epidemiological study was conducted from 2019 to 2023, with participants randomly selected from different risk groups. Blood samples were collected and tested using ELISA for Anti-HEV IgG and IgM markers. Seroprevalence was calculated with 95% confidence intervals, and statistical analyses were conducted using Epi Info 7.2 software. Results. Among 794 tested blood donors, 9.6% (95% CI: 7.7-11.8) were positive for Anti-HEV IgG, indicating past exposure, and 8.3% (95% CI: 6.3-10.8) for Anti-HEV IgM, suggesting recent infection. Hemodialyzed patients had a significantly higher seroprevalence: 45.8% (95% CI: 34.8–57.1) for Anti-HEV IgG and 21.6% (95% CI: 9.8–38.2) for Anti-HEV IgM. Medical workers exhibited moderate IgG prevalence at 11.8% (95% CI: 9.1-15.0) and substantially higher IgM prevalence at 38.1% (95% CI: 26.1-51.2). TB patients had lower IgG (11.9%, 95% CI: 7.8-17.2) and IgM (7.8%, 95% CI: 3.6-14.3) prevalences. IDUs had a notable IgG prevalence of 20.5% (95% CI: 12.6-30.4) but no detectable IgM. Conclusions. This study highlights the significant burden of hepatitis E virus infection among at-risk populations in the Republic of Moldova.
- 1 December 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (4) , 22-29
Disability-adjusted life years associated with liver-related complications among patients with Delta viral infection in Republic of Moldova
Introduction. Disability-adjusted life years (DALY) is a multidimensional measure used to quantify specific tasks of the disease. Chronic liver disease attributed to hepatitis Delta virus (HDV) is one of the major causes that contribute to morbidity and mortality in our country. The DALY estimate in HDV-induced liver disease has the potential to highlight both fatal and nonfatal outcomes of the disease and thus, help in policy making and allocation of health resources. Material and methods. This was an analytical prognostic study conducted in the 2021–2024 period, with the enrollment of 104 patients with HDV-induced liver disease. YLL was predictively rated using Child-Pugh’s estimate of the remaining years of life. The chronic liver disease questionnaire was used to evaluate patients’ disabilities along with the disability weights of the Global Burden of Disease study, calculating YLD. The impact of DALY was interpreted according to the patient’s safety indicators. Results. 104 patients with HDV, originating in different areas of the country, were evaluated, with an average age of 56 ±4.5 years. Substantial YLD losses caused by HDV were mainly reported in working class. The greatest losses of YLD and DALY were caused by cirrhosis of the liver, followed by hepatocellular carcinoma. A great rate of mortality attributed to HDV was seen in the 45-59 and 60-74 age group. A total of 739.1 YLL in male gender and 719.5 in females were recorded for cirrhosis. Overall, men attest a DALY value of 1358.44 total/29.53 per person, and women registered – 1477.3total /25.47 per person. Conclusions. Chronic liver disease attributed to HDV is a medical challenge in Republic of Moldova. Loading the national medical system with serious and overwhelmed patients, make the DALY calculation approach a priority setting.
- 1 December 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (4) , 22-29
Disability-adjusted life years associated with liver-related complications among patients with Delta viral infection in Republic of Moldova
Introduction. Disability-adjusted life years (DALY) is a multidimensional measure used to quantify specific tasks of the disease. Chronic liver disease attributed to hepatitis Delta virus (HDV) is one of the major causes that contribute to morbidity and mortality in our country. The DALY estimate in HDV-induced liver disease has the potential to highlight both fatal and nonfatal outcomes of the disease and thus, help in policy making and allocation of health resources. Material and methods. This was an analytical prognostic study conducted in the 2021–2024 period, with the enrollment of 104 patients with HDV-induced liver disease. YLL was predictively rated using Child-Pugh’s estimate of the remaining years of life. The chronic liver disease questionnaire was used to evaluate patients’ disabilities along with the disability weights of the Global Burden of Disease study, calculating YLD. The impact of DALY was interpreted according to the patient’s safety indicators. Results. 104 patients with HDV, originating in different areas of the country, were evaluated, with an average age of 56 ±4.5 years. Substantial YLD losses caused by HDV were mainly reported in working class. The greatest losses of YLD and DALY were caused by cirrhosis of the liver, followed by hepatocellular carcinoma. A great rate of mortality attributed to HDV was seen in the 45-59 and 60-74 age group. A total of 739.1 YLL in male gender and 719.5 in females were recorded for cirrhosis. Overall, men attest a DALY value of 1358.44 total/29.53 per person, and women registered – 1477.3total /25.47 per person. Conclusions. Chronic liver disease attributed to HDV is a medical challenge in Republic of Moldova. Loading the national medical system with serious and overwhelmed patients, make the DALY calculation approach a priority setting.
- Open Access
- 18 June 2024
- Published by Wiley in Liver International
- Vol. 44 (9) , 2442-2457
Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network
Background and Aims: Chronic hepatitis delta represents a major global health burden. Clinical features of hepatitis D virus (HDV) infection vary largely between different regions worldwide. Treatment approaches are dependent on the approval status of distinct drugs and financial resources.Methods: The Hepatitis Delta International Network (HDIN) registry involves researchers from all continents (Wranke, Liver International 2018). We here report long‐term follow‐up data of 648 hepatitis D patients recruited by 14 centres in 11 countries. Liver‐related clinical endpoints were defined as hepatic decompensation (ascites, encephalopathy and variceal bleeding), liver transplantation, hepatocellular carcinoma or liver‐related death.Results: Patient data were available from all continents but Africa: 22% from Eastern Mediterranean, 32% from Eastern Europe and Central Asia, 13% from Central and Southern Europe, 14% from South Asia (mainly Pakistan) and 19% from South America (mainly Brazil). The mean follow‐up was 6.4 (.6–28) years. During follow‐up, 195 patients (32%) developed a liver‐related clinical event after 3.5 (±3.3) years. Liver cirrhosis at baseline and a detectable HDV RNA test during follow‐up were associated with a worse clinical outcome in multivariate regression analysis while patients receiving interferon alfa‐based therapies developed clinical endpoints less frequently. Patients from South Asia developed endpoints earlier and had the highest mortality.Conclusions: The HDIN registry confirms the severity of hepatitis D and provides further evidence for HDV viraemia as a main risk factor for disease progression. Hepatitis D seems to take a particularly severe course in patients born in Pakistan. There is an urgent need to extend access to antiviral therapies and to provide appropriate education about HDV infection.
- 18 June 2024
- Published by Wiley in Liver International
- Vol. 44 (9) , 2442-2457
Open AccessLong‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network
Background and Aims: Chronic hepatitis delta represents a major global health burden. Clinical features of hepatitis D virus (HDV) infection vary largely between different regions worldwide. Treatment approaches are dependent on the approval status of distinct drugs and financial resources.Methods: The Hepatitis Delta International Network (HDIN) registry involves researchers from all continents (Wranke, Liver International 2018). We here report long‐term follow‐up data of 648 hepatitis D patients recruited by 14 centres in 11 countries. Liver‐related clinical endpoints were defined as hepatic decompensation (ascites, encephalopathy and variceal bleeding), liver transplantation, hepatocellular carcinoma or liver‐related death.Results: Patient data were available from all continents but Africa: 22% from Eastern Mediterranean, 32% from Eastern Europe and Central Asia, 13% from Central and Southern Europe, 14% from South Asia (mainly Pakistan) and 19% from South America (mainly Brazil). The mean follow‐up was 6.4 (.6–28) years. During follow‐up, 195 patients (32%) developed a liver‐related clinical event after 3.5 (±3.3) years. Liver cirrhosis at baseline and a detectable HDV RNA test during follow‐up were associated with a worse clinical outcome in multivariate regression analysis while patients receiving interferon alfa‐based therapies developed clinical endpoints less frequently. Patients from South Asia developed endpoints earlier and had the highest mortality.Conclusions: The HDIN registry confirms the severity of hepatitis D and provides further evidence for HDV viraemia as a main risk factor for disease progression. Hepatitis D seems to take a particularly severe course in patients born in Pakistan. There is an urgent need to extend access to antiviral therapies and to provide appropriate education about HDV infection.
- 1 April 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (1) , 19-26
The impact of family screening in patients with Wilson’s disease from the Republic of Moldova
Introduction. Wilson’s disease (WD) is a rare genetic disease with autosomal recessive transmission, thus screening of all family members of newly diagnosed patients is recommended. Therefore, we aimed to analyze the proband’s family members to detect asymptomatic cases and early treatment initiation. Material and methods. There were retrospectively evaluated 12 families, between 2008 - 2023. The Leipzig Scoring System was used to assess the diagnosis. Genetic testing was performed in all cases by the Sanger sequencing method, examining exons with a high and moderate frequency of mutations. Results. All patients were of Caucasian origin, and originally from Moldova. No patient reported consanguineous relationships. In 9 families, first-degree relatives were tested - parents and siblings, in the other 3 cases only their descendants were evaluated. In 6/12 cases: both parents were healthy carriers; in the other 3 families, one parent was a healthy carrier, but the other parent had not been tested. Among siblings, 4 healthy carriers and 2 healthy siblings were identified. 7 new family members with WD were identified in 5/12 families. 6 patients were asymptomatic, and 1 - was symptomatic. The most frequent mutations detected were p.H1069Q and p.G1341D, both as compound heterozygous and homozygous recessive. A rare mutation has been detected. Discussions. Genetic counseling is important for the family of the patient with Wilson’s disease, as the evaluation of first-degree relatives is recommended by all international guidelines. First-degree relatives include the proband’s siblings, as well as the proband’s offspring and parents. It is also important to assess distant relatives, especially in more isolated areas. Although it is an autosomal recessive disorder, systemic family screening is recommended, as cases of paradoxical transmission are recorded. The c.2292C>T variant, identified in one patient, represents a rare mutation that, when occurring in combination with another pathogenic mutation or a homozygous state, can cause WD. Conclusions. Family screening greatly influences identifying asymptomatic members with Wilson’s disease. Genetic testing is very important in differentiating healthy carriers from asymptomatic members, especially when deciding treatment tactics.
- 1 April 2024
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 11 (1) , 19-26
The impact of family screening in patients with Wilson’s disease from the Republic of Moldova
Introduction. Wilson’s disease (WD) is a rare genetic disease with autosomal recessive transmission, thus screening of all family members of newly diagnosed patients is recommended. Therefore, we aimed to analyze the proband’s family members to detect asymptomatic cases and early treatment initiation. Material and methods. There were retrospectively evaluated 12 families, between 2008 - 2023. The Leipzig Scoring System was used to assess the diagnosis. Genetic testing was performed in all cases by the Sanger sequencing method, examining exons with a high and moderate frequency of mutations. Results. All patients were of Caucasian origin, and originally from Moldova. No patient reported consanguineous relationships. In 9 families, first-degree relatives were tested - parents and siblings, in the other 3 cases only their descendants were evaluated. In 6/12 cases: both parents were healthy carriers; in the other 3 families, one parent was a healthy carrier, but the other parent had not been tested. Among siblings, 4 healthy carriers and 2 healthy siblings were identified. 7 new family members with WD were identified in 5/12 families. 6 patients were asymptomatic, and 1 - was symptomatic. The most frequent mutations detected were p.H1069Q and p.G1341D, both as compound heterozygous and homozygous recessive. A rare mutation has been detected. Discussions. Genetic counseling is important for the family of the patient with Wilson’s disease, as the evaluation of first-degree relatives is recommended by all international guidelines. First-degree relatives include the proband’s siblings, as well as the proband’s offspring and parents. It is also important to assess distant relatives, especially in more isolated areas. Although it is an autosomal recessive disorder, systemic family screening is recommended, as cases of paradoxical transmission are recorded. The c.2292C>T variant, identified in one patient, represents a rare mutation that, when occurring in combination with another pathogenic mutation or a homozygous state, can cause WD. Conclusions. Family screening greatly influences identifying asymptomatic members with Wilson’s disease. Genetic testing is very important in differentiating healthy carriers from asymptomatic members, especially when deciding treatment tactics.